GSK déjà vu: Time for a top-down switch as new CEO tries to conquer old R&D demons
Close to a decade ago, GSK CEO Andrew Witty and R&D chief Moncef Slaoui decided they needed to do something new and different to fire up a lackluster R&D group, looking to shock a system where researchers were far too focused on hanging on to unpromising drugs.
Now, new CEO Emma Walmsley says she has inherited the exact same problem they vowed to fix.
Walmsley notes the company needs new blockbuster drugs that can bring in more than a billion dollars each if she expects to liven things up on the bottom line. Analysts (hello, GSK) have been saying the same thing for years, shaking their heads over the drug approvals that did come through without much chance of changing the game in the diseases they addressed.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.